SOPH Stock Recent News

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023.

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio.

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its SOPHiA DDM™ Platform is now CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR). IVDR certification is a significant regulatory milestone that validates the powerful analytical capabilities of the SOPHiA DDM™ Platform and allows customers throughout the European Union and other markets recognizing this certification to use the SOPHiA DDM™ Platform to support patient diagnostics.

The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter  2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-over-year Gross margins were 68.2% on a reported basis and 73.2% on an adjusted basis, up from 66.7% and 70.0% in the prior year period, respectively Operating loss was $15.0 million on a reported basis and $9.9 million on an adjusted basis, representing year-over-year improvements of 25% and 32%, respectively 2024 Financial Outlook Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to FY 2023 Adjusted gross margin

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders.

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024  /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities.